BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29850149)

  • 1. Induction chemoradiotherapy versus induction chemotherapy for potentially resectable stage IIIA (N2) non-small cell lung cancer: a systematic review and meta-analysis.
    Tong S; Qin Z; Wan M; Zhang L; Cui Y; Yao Y
    J Thorac Dis; 2018 Apr; 10(4):2428-2436. PubMed ID: 29850149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis.
    Chen Y; Peng X; Zhou Y; Xia K; Zhuang W
    World J Surg Oncol; 2018 Jan; 16(1):8. PubMed ID: 29338734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis.
    Ren Z; Zhou S; Liu Z; Xu S
    J Thorac Dis; 2015 Aug; 7(8):1414-22. PubMed ID: 26380768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
    Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
    ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
    Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
    Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer.
    Shah AA; Berry MF; Tzao C; Gandhi M; Worni M; Pietrobon R; D'Amico TA
    Ann Thorac Surg; 2012 Jun; 93(6):1807-12. PubMed ID: 22632486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis.
    Li D; Li W; Pang Y; Xu L; Xu X
    Medicine (Baltimore); 2022 Jul; 101(28):e29580. PubMed ID: 35839033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
    Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative Radiotherapy for Patients With Resectable Stage III-N2 Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Lei T; Li J; Zhong H; Zhang H; Jin Y; Wu J; Li L; Xu B; Song Q; Hu Q
    Front Oncol; 2021; 11():680615. PubMed ID: 34336667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Chen D; Jin Z; Zhang J; Xu C; Zhu K; Ruan Y; Zhang B; Chen B; Shen J
    Front Surg; 2021; 8():715318. PubMed ID: 34490338
    [No Abstract]   [Full Text] [Related]  

  • 13. Surgery for early stage non-small cell lung cancer.
    Manser R; Wright G; Hart D; Byrnes G; Campbell DA
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004699. PubMed ID: 15674959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Couñago F; Rodriguez de Dios N; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
    Lung Cancer; 2018 Apr; 118():119-127. PubMed ID: 29571989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Montemuiño S; Dios NR; Martín M; Taboada B; Calvo-Crespo P; Samper-Ots MP; López-Guerra JL; López-Mata M; Jové-Teixidó J; Díaz-Díaz V; Ingunza-Barón L; Murcia-Mejía M; Chust M; García-Cañibano T; Couselo ML; Puertas MM; Cerro ED; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Couñago F
    Rep Pract Oncol Radiother; 2020; 25(3):447-455. PubMed ID: 32477011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of surgery in N2 NSCLC: pros.
    Shien K; Toyooka S
    Jpn J Clin Oncol; 2016 Dec; 46(12):1168-1173. PubMed ID: 27655902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mediastinal radiotherapy after adjuvant chemotherapy for resected non-small cell lung cancer with N2 lymphadenopathy: A novel meta-analysis.
    Harling L; Jayakumar S; Ashrafian H; Bille A; Toufektzian L; Smith D
    JTCVS Open; 2021 Mar; 5():121-130. PubMed ID: 36003173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Chemoradiotherapy vesus Chemotherapy alone Followed by Surgery for Resectable Stage III Non-Small-Cell Lung Cancer: a Meta-Analysis.
    Guo SX; Jian Y; Chen YL; Cai Y; Zhang QY; Tou FF
    Sci Rep; 2016 Sep; 6():34388. PubMed ID: 27677242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.